Oct 07, 2022 / 03:20PM GMT
Robert Brown - University of Massachusetts Medical Center and Medical School - Professor & Chair of Neurology
(audio in progress) who is the Chief Development Officer at Brainstorm, is going to discuss the relationship between CSF biomarkers and treatment efficacy of NurOwn [stem cell therapy].
Stacy Lindborg - Brainstorm Cell Therapeutics Inc. - EVP & Chief Development Officer
Thank you, Bob, and thank you for the opportunity to share insights into the rich biomarker data from our Phase 3 trial. It's important that I provide some context before I go into the objectives for today and the results because the broader context of the trial actually drive some of our objectives. And as we publish this trial, you'll likely be aware that this trial included participants with advanced ALS, resulting in participants hitting a floor effect on the ALSFRS-R.
As you can see by the footnote on this on the slide, about a quarter of participants had ALSFRS-R values of 25 or below at baseline. And how the patient population from our Phase 3 trial compares to
Brainstorm Cell Therapeutics Inc ALS One Research Symposium Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers